IDH1 and glioblastoma: Genetic specificity of GBM (e.g., IDH1 mutation, EGFR mutation/amplification, NF1 mutation/deletion, and PDGFRa amplification) leads to tumor heterogeneity and adaptability, thus mediating the difference in disease prognosis and chemotherapy sensitivity (5, 6).